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Summary Prostaglandins are synthesized from arachidonic acid by the enzyme cyclo-oxygenase. There are two isoforms of cyclo-
oxygenases: COX-1 (a constitutive form) and COX-2 (an inducible form). COX-2 has recently been categorized as an immediate-early gene
and is associated with cellular growth and differentiation. The purpose of this study was to investigate the effects of exogenous
dimethylprostaglandin E2 (dmPGE2) on prostate cancer cell growth. Results ofthese experiments demonstrate that administration of dmPGE2
to growing PC-3 cells significantly increased cellular proliferation (as measured by the cell number), total DNA content and endogenous PGE2
concentration. DmPGE2 also increased the steady-state mRNA levels of its own inducible synthesizing enzyme, COX-2, as well as cellular
growth to levels similar to those seen with fetal calf serum and phorbol ester. The same results were observed in other human cancer cell
types, such as the androgen-dependent LNCaP cells, breast cancer MDA-MB-134 cells and human colorectal carcinoma DiFi cells. In PC-3
cells, the dmPGE2 regulation of the COX-2 mRNA levels was both time dependent, with maximum stimulation seen 2 h after addition, and
dose dependent on dmPGE2 concentration, with maximum stimulation seen at 5[sg ml-'. The non-steroidal anti-inflammatorydrug flurbiprofen
(5 FM), in the presence of exogenous dmPGE2, inhibited the up-regulation of COX-2 mRNA and PC-3 cell growth. Taken together, these data
suggest that PGE2 has a specific role in the maintenance of human cancer cell growth and that the activation of COX-2 expression depends
primarily upon newly synthesized PGE2, perhaps resulting from changes in local cellular PGE2 concentrations.
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Arachidonic acid (AA) is derived from linoleic acid (LA) through
two majorreactions: desaturation (catalysed by delta-6 desaturase)
and elongation (by elongase) of LA to produce dihomogamma-
linolenic acid (20:3) intermediate, followed by a desaturation step
catalysed by delta-5-desaturase to produce AA (Zurier, 1993). AA
is then transformed to prostaglandins (PGs) and thromboxanes
(TXs) by the enzyme prostaglandin endoperoxide synthase (PES),
also referred to as cyclo-oxygenase (COX; EC 1.14.99.1)
(Needleman et al, 1986; Smith, 1992). This enzyme catalyses two
enzymatic reactions: oxygenation of AA into PGG2 followed by
peroxidation ofPGG2 into PGH2 (Needleman et al, 1986). PGH2 is
subsequently isomerized and reduced to the major biologically
active prostanoids: PGE2, PGF2a, prostacyclin (PGI2) or throm-
boxane A2 (Smith, 1992).
Mammalian cells contain at least two isozymes of cyclo-
oxygenase: COX-1 and COX-2. COX-1 is a well-characterized,
constitutively expressed enzyme originally purified from ovine
and bovine vesicular glands and platelets (Smith, 1992; Smith et
al, 1991). The cDNA clones ofthe 2.8-kb COX-l mRNA isolated
from ovine (DeWitt and Smith, 1988), murine (DeWitt et al, 1990)
and human tissues (Funk et al, 1991) encodes a protein of approx-
imately 600 amino acids in length. The cDNA clones ofthe 4.4-kb
COX-2 message have been isolated from various tissues ofhuman
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and animal origin and also encode a protein of about 600 amino
acids (Fletcher et al, 1992; Hla and Neilson, 1992). COX-1 and
COX-2 polypeptides share 61% primary sequence identity
(Appleby et al, 1994). The expression of COX-2 mRNA and/or
protein, however, has been shown to be induced in a variety of
cells following addition of serum in src-transformed chicken
fibroblasts (Xie et al, 1991), differentiation factors such as
lipopolysaccharides in human and animal macrophages (Hla and
Neilson, 1992), tumour-promoter phorbol ester (Kujubu and
Herschman, 1992), growth factors (Hamasaki et al, 1993) and
cytokines such as tumour necrosis factor and interleukin la (Chen
et al, 1994; Ristimaki et al, 1994).
There is evidence showing correlation between the levels of
arachidonic acid metabolites and tumorigenesis. For example, in the
skin model of mouse carcinogenesis, the administration of tumour-
promoting agents tetradecanoylphorbacetate (TPA) or 7-bromo-
methylbenz[a]anthracene to mouse epidermis induces accumulation
ofhigh levels ofPGE2 (Furstenberger and Marks, 1980; Yamamoto
et al, 1992). Many non-steroidal anti-inflammatory drugs (NSAIDs),
such as aspirin, indomethacin and sulindac, have been shown to
inhibitthegrowth ofcolontumours induced bychemical carcinogens
in rodents (Narisawa et al, 1982; Reddy et al, 1987). In addition,
recentepidemiological studies with large numbers ofhuman patients
show that the frequent use of aspirin or other NSALDs acts as a
protective agent against colon and rectal cancers (Thun et al, 1991,
1993). However, it is unclear whether this is due to a direct effect of
NSAIDs, mediatedby the inhibition ofprostaglandin synthesis, orby
other factors indirectly associated with NSAID use.
Prostate cancer is one of the commonest cancers in the elderly
malepopulation andits aetiologyremainsunknown. Epidemiological
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studies on carcinoma ofthe prostate have revealed a link between the
development ofdisease and consumption ofdietary fats (Graham et
al, 1983). Recent studies by Rose and Connolly (Rose and Connolly,
1991; Connolly and Rose, 1992) have shown that growth of the
androgen-unresponsive PC-3 human prostate cancer cells is stimu-
lated in vitro by the addition ofthe omega-6 polyunsaturated LA and
inhibited by NSAIDs such as indomethacin, esculetin andpiroxicam.
Thegrowth effects ofessential fatty acids appearto involve both PGs
and leukotrienes (LTs), which interconnect with autocrine regulation
through epidermal growth factor-related polypeptides (Connolly and
Rose, 1992; Rose and Connolly, 1992). Moreover, Wahle and co-
workers have also shown thathuman malignantprostatic tissues have
significantly reduced AA concentration compared with benign tissue
(Chaudry et al, 1991). When these investigators followed the metab-
olismoflabelledAA, significant amounts oftheradioactive label was
found in PGE2 in both benign and malignant prostatic tissues, with
the malignant tissues converting radiolabelled AA to PGE2 at an
almost 10-fold higher rate than benign tissues (Chaudry et al, 1994).
Thedatasuggest aspecific role forPGE2inmaintaining thegrowthof
malignant prostatic tissues.
The present studies were designed to investigate the effects of
exogenous PGE2 on cellular growth as well as on COX-2 expres-
sion in the human prostatic adenocarcinoma PC-3 cell line. We
have shown previously that PGE2 acts as an autocrine growth
factor in the growth of osteoblast MC3T3-E1 cells (Hughes-
Fulford et al, 1992). PGE2 also up-regulates the expression of
immediate-early genes, such as c-fos and c-jun, and increases
DNA synthesis and bone cell number in comparison with non-
treated cells (Hughes-Fulford et al, 1992). We reasoned that, if
PC-3 is responsive to growth stimulation by linoleic acid, then it
may also be responsive to growth stimulation by PGE2. Indeed,
our data suggest that PGE2 at the micromolar level is able to stim-
ulate PC-3 cell growth, partly through up-regulation of COX-2
mRNA levels and newly synthesized PGE2.
MATERIALS AND METHODS
Materials
16,16-Dimethyl-PGE2 (dmPGE2) was obtained from Cayman
Chemical (Ann Arbor, MI, USA). Flurbiprofen, actinomycin D
and cycloheximide were purchased from Sigma Chemical (St
Louis, MO, USA). RPMI-1640 medium, L-glutamine and trypsin
were obtained from UCSF Cell Culture Facility (San Francisco,
CA, USA). Fetal bovine serum was purchased from Gibco
BRL (Gaithersburg, MD, USA). Antibiotic-antimycotic solution
(containing penicillin, streptomycin and amphotericin B) was
obtained from Sigma Cell Culture (St Louis, MO, USA).
Cell culture
Human prostatic carcinoma PC-3 and LNCaP and human breast
cancer cells were grown in T-150 flasks with 10% fetal bovine
serum (FBS) containing RPMI-1640 medium supplemented with
2 mM L-glutamine and 100 U ofpenicillin 0.1 mg of streptomycin
and 0.25 lig of amphotericin B. The DiFi cells were grown in a
combination of Dulbecco's Modified Eagle Medium (DMEM)
H-21 and Leibovitz L-15 (50:50) medium supplemented with 1%
insulin/transferrin/selenite, 2 mM L-glutamine and 100 U of peni-
cillin, 0.1 mg ofstreptomycin and 0.25 ,tg ofamphotericin B. Cells
were maintained at high density in a 37°C incubator with 5%
carbon dioxide and fed three times a week. Twenty-four hours
before cell platings, cell stocks were fed with fresh 10% FBS-
containing medium. For each experiment, cells were plated out in
0.3% FBS-containing medium in 100-cm2 culture dishes at a cell
density of approximately 6 x 105 cells per dish. Cells were incu-
bated under these conditions for another 48 h to synchronize the
growth and to deplete any residual serumgrowth factors thatmight
be present in the culture medium. Each experiment was done at
least three times, and the results were found to be consistent.
DmPGE2 was used as this PGE2 analogue is a stable compound
withthe samebiological activity. Longerincubation ofnativePGE2
results in the breakdown ofthe compound and therefore the use of
a stable analogue is necessary when some of the experiments
involve long incubation periods. The concentrations of exogenous
dmPGE2 used in all experiments were in the range 1-10 [tg ml-1, as
this range has been found to be effective in stimulating DNA
synthesis in osteoblast cell lines (Hughes-Fulford et al, 1992).
Furthermore, during G, phase, subconfluent synchronized
osteoblast cells make approximately 5-10 ng of PGE2 (-1.7-
3.4 FtM) (Hughes-Fulford et al, 1992).
RNA isolation
RNA was extracted and purified by the acid guanidium thio-
cyanate-phenol-chloroform extraction method (RNA Stat-60
reagent), according to the procedure recommended by the manu-
facturer (TelTest 'B', Friendswood, TX, USA). One millilitre of
the RNA Stat-60 reagent was added directly to the culture dishes
and the cells were scraped and collected into 1.5-ml siliconized
microfuge tubes. Two hundred microlitres ofchloroform was then
added and the tubes were shaken vigorously to extract the RNA
and allowed to sit at room temperature for 2-3 min. The
homogenate was centrifuged at 12 000 g for 15 min at 4°C.
Following centrifugation, the colourless aqueous upper layer was
carefully removed and transferred to a fresh tube. An equal
volume (550-600 [tl) of isopropanol was then added to the tubes
and the samples were stored at 40C overnight. The tubes were
centrifuged the next day and the RNA precipitates appeared as a
white pellet in the bottom ofthe tubes. The pellet was washed once
with isopropanol and subsequently dried at room temperature for
5-10 min. The RNA was then resuspended in diethylpyrocar-
bonate-treated (DEPC) water and run on a 0.5% agarose gel.
Quantitation of RNA was performed on GeneQuant spectropho-
tometer (Pharmacia LKB Biotechnology, Piscataway, NJ, USA).
RT-PCR analysis
An aliquot of 1.5 [tg of RNA was reverse-transcribed in the pres-
ence of deoxynucleotides (Boehringer Mannheim, Indianapolis,
IN, USA), oligo-(dT)12 18 primer (Gibco BRL), RNAase inhibitor
(Boehringer Mannheim), M-MLV reverse transcriptase (Gibco
BRL), first-strand buffer supplied together with the M-MLV
reverse-transcriptase enzyme and sufficient DEPC-treated water to
make up the 30 itl total volume per reaction. The reverse transcrip-
tion (RT) was carried out in Robocycler 40 temperature cycler
(Stratagene, San Diego, CA, USA) with ahybridization step at 30°C
for 10 min, RT at 42°C for 42 min, denaturation at 99°C for 5 min
and cooling down at 6°C for 5 min. The polymerase chain reaction
(PCR) portion was carried out in a total volume of50[tl in a 500-pl
microfuge tube containing single-stranded cDNA from the RT
sample, magnesium chloride (Gibco BRL), each deoxynucleotide
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Figure 1 Changes in PC-3 cell number (A) and endogenous PGE2 (B) in
response to dmPGE2 stimulation. PC-3 cells were plated in six-well plates
(1.2 x 105 cells per well) in 4 ml of RPMI-1640 medium containing 2% fetal
bovine serum supplemented with antibiotics/antimycotics. The cells were
grown for a period of 2 days in the absence and presence of exogenous
dmPGE2 (5 1tg ml-1). Each day, the cells were counted for increase in the cell
number and the cellular medium was collected for PGE2 concentration
measurements, as described in the Materials and methods section. The data
are presented as an average ± s.d. oftriplicate treatments. **P < 0.05, and
***P < 0.01
(Boehringer Mannheim), Taq DNA polymerase (Gibco BRL), PCR
buffer supplied with the Taq DNA polymerase, sense and antisense
gene primers and sufficient deionized water to make up the 50 RI
total volume. Theprimers used forpriming the COX-2 gene were as
follows: sense, 5'-GTG CCT GGT CTG ATG ATG TAT GC; and
anti-sense, 5'-CCA TAA GTC CTT TCA AGG AGA ATG. The
P=0.0008
P<o.0001
P<0.0001
1*
Control 10%FBS TPA PGE2
Figure 2 (A) Comparison in COX-2 mRNA accumulation in response to
various growth stimulators. PC-3 cells were grown and serum depleted in
100-mm culture dishes (6 x 105 cells per plate) in RPMI medium containing
0.3% serum for a period of 48 h. At time 0, cells were treated with either
nothing (ethanol), 10% serum, phorbol ester TPA (1.6 FtM), or dmPGE2
(5 [tg ml-' in ethanol). Three hours later, cells were harvested and the RNA
was isolated as described in the Materials and methods section. The results
are presented as the level of COX-2 mRNA induction in comparison to the
control. The data are representative of three experiments. Relative pixel
densities corrected to internal standard: 1 (control), 3.97 (10% serum), 3.81
(TPA) and 4.46 (dmPGE2). (B) Comparison in cellular proliferation in
response to growth stimulators. PC-3 cells at a density of 10 000 cells per
well in 1% fetal calf serum-containing medium were seeded in a 96-well
plate. Five hours later, 10% serum, phorbol ester TPA (1.6 FM) or dmPGE2
(5 [tg ml-' in ethanol) were added to the wells. DNA content was determined
by using the Hoechst dye as described in Materials and methods after a 24-h
growth period. The data are presented as an average ± s.d. of triplicate
treatments
primers used for priming the internal standard f3-actin were: sense,
5'-CCG CAA ATG CTT CTA GGC; and anti-sense, 5'-GGT CTC
ACG TCA GTG TAC GG. The temperature cycling was performed
in the Robocycler 40 temperature cycler, with the initial start
performed at94°C for 1 min40 s, the melting step at630C for 1 min
10 s and the annealling and extending step at 72°C for 1 min 40 s.
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PCR bands were identified by size after electrophoresis on a 1%
agarose gel in tris-acetate-EDTA (TAE) buffer. The gel was run on
a Hoeffer mini-gel apparatus at a constant voltage of 125 V for
approximately 30 min, stained with ethidium bromide, viewed by
UV light, andphotographed with adirect-screen instant cameraDS-
34 (Polaroid, Cambridge, MA, USA). For quantification, the bands
ofinterest were scanned at 400 dpi with an HP Scanjet Ilcx scanner
(Hewlett-Packard, Palo Alto, CA, USA) and stored as Macintosh
TIFFfiles. The peak areas anddensities were determinedusing NIH
Image 1.55 program written by Wayne Rasband at the US National
Institutes of Health, Bethesda, MD, USA. All measurements of
increases inCOX-2 mRNAhave been corrected to the internal stan-
dard (P-actin) and are reported as fold of increase from the control
in each figure legend.
Cell number and measurement of DNA content
Cell counting was performed using the ZBI Coulter counter
(Coulter Electronics, Hialeah, FL, USA) with isotonic buffered
saline solution (Baxter, Deerfield, IL, USA) as blanks. Briefly,
cells were plated out in Falcon six-well plates (Becton Dickenson,
Lincoln Park, NJ, USA) in 0.3% FBS-containing RPMI-1640
medium with and without treatments. Following 24-h and 48-h
treatments, cells were trypsinized and collected into 15-ml conical
tubes. The trypsin was neutralized by adding 1 ml of medium-
containing 10% FBS to the sample and 100-i.l volumes were
counted using the Coulter counter. Direct measurement of DNA
content was performed using the Fluoroskan II fluorometer
(Labsystems, Needham Heights, MA, USA). Briefly, cells were
plated out in 96-well plates in a total medium volume of 200 p.1.
Following 24-h treatment, 3 it1 of Hoechst dye no. 33258 1 mg
ml-' (Calbiochem, San Diego, CA, USA) was added to individual
wells and incubated for 30 min in the 370C incubator. Cells were
then washed three times with phosphate-buffered saline, and the
fluorescence was read using the fluorometer with the excitation
wavelength set at 346 nm and the emission at 460 nm.
PGE2 analysis
The exogenous PGE2 levels were quantitated using the PGE2
Monoclonal Enzyme Immunoassay Kit (Cayman Chemical, Ann
Arbor, MI, USA), according to the protocol recommended by the
manufacturer. This kit assay system is very specific for native
PGE2 and does not detect dmPGE2 or any prostaglandin of other
series (A, B, D or F). The samples contained in the 96-well plate
were read at 410 nm using the Dynatech MR5000 Microplate
Reader (Dynatech Laboratories, Chantilly, VA, USA), and the
data were analysed with the BioLinx 2.0 Software (Dynatech
Laboratories) run on an IBM-compatible PC.
RESULTS
Changes in PC-3 cell number and endogenous PGE2 in
response to exogenous dmPGE2 administration
The effect ofexogenous dmPGE2 on the growth ofprostatic carci-
noma PC-3 cells is shown in Figure lA. PC-3 cells grew linearly
from day 0 to day 2. The cell growth rate was highest between
days l and 2. Exogenous dmPGE2 at a concentration of 5 gig ml-'
was able to increase the cell numberby 1.5-fold compared withthe
control cultures seen at the end ofthe 2-day treatment period. This
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Figure 3 Time course of COX-2 mRNA induction following dmPGE2
administration. PC-3 cells were grown in 100-mm culture dishes (9 x 105 cells
per plate) in RPMI medium containing 0.3% serum for a period of 48 h. At
time 0, cells were treated with dmPGE2 (5 9tg ml-1 in ethanol). Control culture
received ethanol only. Cells were harvested at the indicated time and the
RNA was isolated as described in the Materials and methods section. The
results are presented as the relative level of COX-2 mRNA induction in
comparison to the control. The data are representative of three experiments.
Relative pixel densities corrected to internal standard: 1 (0 h), 0.90 (0.5 h),
8.40 (3 h), 4.41 (6 h) and 3.60 (24 h)
increase in cell proliferation was primarily due to a 2.5-fold
increase in growth rate seen during the first day (Figure lA). As
noted in the Materials and methods, the ELISA detects only native
PGE2 and not the synthetic dmPGE2 used in this study to stimulate
growth. Treatment of dmPGE2 also increased the steady-state
endogenous PGE2 concentration by 17-fold from day 0 to day 1
during cell growth compared with the control (Figure iB). At day
2, endogenous PGE2 concentration was threefold higher in the
dmPGE2 treated cells than in the control cells. Thus, a correlation
exists between the increase in cell number and increase in total
endogenous PGE2 content during PC-3 cell growth, suggesting
that the newly synthesized PGE2 plays an important role in main-
taining cell proliferation.
Comparison of COX-2 message induction and changes
in cell growth in response to various growth
stimulators
It has been previously reported that COX-2 expression was stimu-
lated by tumour promoter phorbol ester in mouse fibroblasts
(Kujubu et al, 1991; Herschman et al, 1993) as well as in human
vascular endothelial cells (Hla and Neilson, 1992). The effect of
administration of PGE2 on COX-2 mRNA levels was compared
with those ofvarious growth stimulators including 10% serum and
phorbol ester TPA (Figure 2A). Both 10% FBS media and phorbol
ester TPA (1.6 giM) were able to increase the steady-state levels
of COX-2 mRNA accumulation by approximately fourfold
compared with the untreated control. DmPGE2 (5 gig ml-1) up-
regulated COX-2 mRNA levels by 4.5-fold compared with the
control culture. Expression of COX-1, however, was not detected
in the PC-3 cells regardless of the stimulation (data not shown).
We also compared the degree of growth stimulation of dmPGE2
with that of serum and TPA by measuring changes in the total
DNA content following a 24-h growth stimulation (Figure 2B).
Both 10% serum and TPA increased the cellular DNA content by
British Journal of Cancer (1997) 75(8), 1111-1118 . Cancer Research Campaign 1997PGE2 up-regulates COX-2 mRNA in PC-3 cells 1115
COX-2
1-Actin
0 0.5 2 5 10
PGE2 (!'g mli)
Figure 4 The effect of increasing dmPGE2 concentration on COX-2 mRNA
level. PC-3 cells were grown and serum depleted in 100-mm culture dishes
(5.5 x 105 cells per plate) in RPMI medium containing 0.3% serum for a
period of 48 h. At time 0, cells were treated with dmPGE2 (in ethanol) at the
indicated concentration, while the control culture was treated with ethanol
only. Cells were harvested after 3 h of dmPGE2 administration, and the RNA
was isolated as described in the Materials and methods section. The results
are presented as the level of COX-2 mRNA induction in comparison to the
control. The data are representative of three experiments. Relative pixel
densities corrected to internal standard: 1 (control), 2.73 (0.5 gg ml-' of
dmPGE2), 2.97 (2 ig ml-1 of dmPGE2), 3.00 (5 1tg ml-' of dmPGE2) and 0.93
(10 gg ml-' of dmPGE2)
Table The effect of NSAID flurbiprofen on PC-3 cell number and DNA
content
Cell number DNA content
Control 326 000 ± 12 009* 19.38 ± 0.86#
PGE2 569 600 +26 376*.# 38.30 ± 3.99L##
PGE2 + flurbiprofen 285 600 ± 36 739# 27.25 ± 4.28##
For cell number measurement, PC-3 cells were seeded in six-well plates in
2 ml of RPMI-1640 medium containing 0.5% fetal calf serum. The cells were
grown in the presence of nothing (control), PGE2 (5 ,ug ml-') and flurbiprofen
(5 iM). At the end of a 2-day period, cells were counted using a Coulter
counter as described in the Materials and methods section. For DNA content
measurement, PC-3 cells at a density of 20 000 cells per well in 1% fetal calf
serum-containing medium were seeded in a 96-well plate. Five hours later,
PGE2 (5 tg ml-') and/or flurbiprofen (5 iM) were added to the wells. DNA
content was determined by using the Hoechst dye as described in Materials
and methods after a 24-h growth period. The data are presented as an
average ± s.d. of triplicate treatments.*P < 0.0001, #P < 0.0004, UP < 0.05.
1.42- and 1.71-fold compared with the control, whereas dmPGE2
increased the DNA content by 1.64-fold compared with the
control.
Time-dependent changes in the COX-2 mRNA levels
following exogenous dmPGE2 administration
The time course of induction of COX-2 mRNA expression was
investigated over a 3-h period of dmPGE2 treatment to PC-3 cells
(Figure 3). The steady-state COX-2 mRNA began to increase
somewhere between 1 and 2 h following the addition ofexogenous
dmPGE2. At 3 h, the COX-2 mRNA reached its highest levels at
8.4-fold above the levels seen at the time oftreatment. Beyond 3 h,
the COX-2 mRNA levels decreased significantly and could still be
detected at the 24-h time point with levels 3.6-fold higher than
those ofthe control.
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Figure 5 Induction of COX-2 gene expression in LNCaP cells (A) and DiFi
and MDA-MB-134 cells (B). LNCaP cells were grown in T-75 flasks to 80%
confluency in RPMI-1640 medium. The cells were serum deprived overnight
by growing them in 1% serum-containing medium. Cells were then treated
with 5 9g ml-' PGE2 in ethanol and harvested at the indicated time.
Approximately 9 x 105 cells of both MDA-MB-134 and DiFi cells were grown
in RPMI-1640 and a combination of DMEM H-21/Leibovitz L-15 media,
respectively, and were serum deprived for a 24-h period. PGE2 (5 jg ml-' in
ethanol) was then administered to the culture medium. The control culture
received ethanol only. Cells were then harvested after 24 and 6 h of PGE2
treatment to MDA-MB-134 and DiFi cells respectively. RNA from all three cell
lines was isolated as described in the Materials and methods section. The
data are representative of two experiments each
The effect of increasing exogenous dmPGE2
concentration on COX-2 mRNA level
We investigated the dose-dependent response of exogenous
dmPGE2 treatment on the steady-state COX-2 mRNA levels. As
seen in Figure 4, the COX-2 mRNA levels were stimulated by
0.5 [ig mll dmPGE2 (1.31 FiM) to 2.7-fold higher than the control
level. At a dmPGE2 concentration of 5 .tg per ml of medium the
steady-state COX-2 mRNA accumulation was still up-regulated to
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Figure 6 The effect of NSAID flurbiprofen on COX-2 mRNA accumulation.
PC-3 cells were seeded at 6.6 x 105 cells per plate in 10-mm plates containing
0.3% serum and were serum depleted for a period of 48 h before treatment.
Cells were treated with PGE2 (5 9tg ml-1 in ethanol) in the presence or
absence of 1 and 5 1M offlurbiprofen (F). The control culture was treated with
ethanol only. After 3 h of treatment, the cells were harvested and the RNA
was isolated as described in the Materials and methods section. The results
are presented as the level of COX-2 mRNA induction in comparison to the
control. The data are representative of three experiments. Relative pixel
densities corrected to internal standard: 1 for control, 1.89 for dmPGE2, 0.26
for dmPGE2+ F (1 AtM), and 0.20 dmPGE2+ F (5 gM) respectively
levels slightly above (threefold) those of 0.5 [ig ml dmPGE2.
However, at 10 rtg ml' dmPGE2, COX-2 mRNA accumulation
was significantly decreased from the levels reached at 5 [ig ml
dmPGE2 - back to the control levels.
Induction of COX-2 mRNA by dmPGE2 in other
neoplastic cell lines
We investigated whether the up-regulation of COX-2 mRNA by
dmPGE2 in the PC-3 cells occurred in other prostate cancer cells,
as well as in other cancer cells ofdifferent tissue origins. Another
prostate cancer line, LNCaP, was chosen to illustrate the effect of
dmPGE2 addition on COX-2 mRNA levels, as these cells are
androgen dependent. Figure 5A shows that the LNCaP cells had
high COX-2 mRNA levels, even in resting conditions, which
might be due to an altered regulation of steady-state COX-2
message accumulation. However, as in PC-3 cells, exogenous
dmPGE2 also increased the COX-2 mRNA levels time-depen-
dently, with the highest accumulation seen 2 h after dmPGE2 addi-
tion. We also examined the COX-2 expression in human colonic
carcinoma cells [derived from a familial adenomatous polyposis
(Gardner's syndrome) patient], DiFi cells (Olive et al, 1993) and
human breast carcinoma (MDA-MB-134) cells (Cailleau et al,
1974). As shown in Figure SB, up-regulation COX-2 mRN
accumulation in response to dmPGE2 administration was also
observed in these two cell lines.
The effect of the NSAID flurbiprofen on the COX-2
mRNA accumulation
We further investigated whether the induction ofCOX-2 mRNA is
also regulated by the endogenous dmPGE2. A flurbiprofen
dose-response experiment was carried out to determine whether
newly synthesized PGE2 contributes to the COX-2 mRNA accum-
ulation. The table depicts changes in the cell number as well as in
Control
CHX
PGE2
PGE2+CHX
c: x 0~~~ _i.
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Figure 7 The effect of the translational inhibitor cycloheximide on COX-2
mRNA accumulation. PC-3 cells were seeded at 6.6x 105 cells per 10-mm plate
containing 0.3% serum and were grown to serum depletion for period of 48 h
before treatment. Cells were treated with cycloheximide (CHX) (10 Rg ml-1) 1 h
before PGE2 (5 9tg ml-') addition. The control culture was treated with ethanol
only. Three hours after PGE2 treatment, cells were harvested and the RNA was
isolated as described in the Materials and methods section. The results are
presented as the level of COX-2 mRNA induction in comparison to the control.
The data are representative of three experiments. Relative pixel densities
corrected to internal standard: 1 for control, 6.7 for cycloheximide, 6.8 for
dmPGE2 and 8.2 for cycloheximide + dmPGE2
the DNA contents ofgrowing PC-3 cells in response to exogenous
dmPGE2 in the absence and presence offlurbiprofen. Flurbiprofen
was able to reverse the increase in the cell number as well as DNA
content of the growing cells treated with dmPGE2. As seen in
Figure 6, 1 FtM flurbiprofen markedly decreased the dmPGE2-
induced COX-2 mRNA levels by fivefold compared with the
levels attained when dmPGE2 alone was present. In cells treated
with 5 [iM flurbiprofen, the COX-2 mRNA level was reduced even
further. These data suggest that the newly synthesized, endo-
genous PGE2 is partly responsible for the signal regulating the up-
regulation ofCOX-2 mRNA levels.
The effect of translational inhibitor cycloheximide on
COX-2 mRNA accumulation
In order to determine whether the induction of COX-2 mRNA
accumulation by PGE2 was dependent on new protein synthesis,
cycloheximide was used to block the cellular protein translation
(Figure 7). In the absence ofdmPGE2, cycloheximide increased the
steady-state COX-2 mRNA accumulation to levels about sevenfold
higher than those of the control. DmPGE2, however, only slightly
potentiated the cycloheximide-induced increase in COX-2 mRNA
levels to 1.2-fold above the levels seen with cycloheximide only.
DISCUSSION
The results of this study suggest that dmPGE2 increases PC-3 cell
growth, total DNA content and endogenous PGE2 levels by
inducing COX-2 mRNA transcript. The up-regulation of COX-2
mRNA in PC-3 cells seems to depend partly upon the new
synthesis of PGE2. Moreover, flurbiprofen, a cyclo-oxygenase
inhibitor, is able to decrease both growth and COX-2 mRNA
levels. These findings are interesting as this cell line has previ-
ously been shown to be responsive to growth stimulation by the
omega-6 polyunsaturated LA (an essential fatty acid), which is
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thought to be dependent upon eicosanoid biosynthesis (Rose and
Connolly, 1991).
PGE2, as a downstream metabolite of LA, can increase cell
growth as well as the enzyme responsible for its own synthesis.
Indeed, the data presented in this paper provide the first evidence
that dmPGE2 acts as a non-polypeptide growth factor in cancerous
human cells. Previous studies from ourlaboratory have shown that
dmPGE2 can act as an autocrine growth factor in bone formation
and development both in vivo and in vitro (Hughes-Fulford et al,
1992). Furthermore, PGE2 has recently been implicated in the
growth and differentiation of human B-lymphocytes activated
through their CD40 antigen (Garrone et al, 1994). In spite of the
evidence that PGE2 can act as a growth regulator, other data have
demonstrated thathigh levels ofPGE2 can cause growth arrest and,
potentially, programmed cell death in a number of primary and
established cell lines of immunological origins, such as thymo-
cytes (Suzuki et al, 1991) and B-lymphocytes (Brown et al, 1992).
We, however, did not find any evidence that dmPGE2, at the
concentrations used in this paper (as described in Materials and
methods), promotes cell death in PC-3 cells.
One of the hallmarks of cellular stimulation in response to acti-
vation by hormones, growth factors or phorbol esters is the induc-
tion of the immediate-early gene expression. COX-2 has recently
been classified as a member of this group (Kujubu et al, 1991;
Herschman et al, 1993). There are many lines ofevidence showing
that the gene encoding this enzyme is inducible by varieties of
hormones and growth factors. For example, iloprost (a stable
analogue of prostacyclin), PGE, or PGF2a increases the steady-
state levels ofCOX-2 mRNA andprotein in the mouse osteoblastic
MC3T3-E1 cell line (Takahashi et al, 1994). The data here add to
our knowledge by showing for the first time that PGE2 can up-
regulate the mRNA levels ofits own synthesizing enzyme, COX-2,
in fourhuman cancer cell lines. In this regard, it is conceivable that
the cells continuously sustain their growth in part by using the
extracellular PGE2 that they themselves produce and release to up-
regulate the expressions of COX-2 and possibly other growth-
related genes. Indeed, stimulation ofc-fos and Egr-1 expression by
arachidonic acid in 3T3 fibroblasts has been found to depend upon
PGE2 formation (Danesch et al, 1994). However, at present, we
do not know the exact nature of the supporting role of PGE2 in
the homeostasis of prostate cancer cells, such as that recently
described for breast cancer cells (Schrey and Patel, 1995). These
investigators have found that breast fibroblasts, particularly under
the influence of inflammatory mediators, such as interleukin l1
and bradykinin, provide a potentially rich source for PGE2 produc-
tion in breast cancer cells, whereas significant contributions from
the epithelial tumour component may be restricted to breast cancer
cells exhibiting an invasive phenotype (Schrey and Patel, 1995).
The up-regulation ofCOX-2 mRNA accumulation in PC-3 cells
induced by dmPGE2 partly depends upon the new synthesis of
PGE2 by the cells (Figure 6). However, this up-regulation does
not seem to be due to a direct transcriptional effect of dmPGE2
on the COX-2 gene as the initial peak ofthe induction was seen at
the 3-h time point following addition of exogenous dmPGE2
(Figure 3). If a direct transcriptional effect had occurred, one
would expect an increase in the mRNA levels within 15-30 min
following addition ofPGE2.
The administration of NSAID flurbiprofen decreased PC-3 cell
growth (Table) and increased the COX-2 mRNA level brought
about by exogenous dmPGE2 (Figure 6). However, it is still not
clear to us whether this reduction in cell growth and COX-2
mRNA level was because of a direct inhibitory effect of flur-
biprofen on COX-2 protein or other indirect effects associated
with decreased expression of other growth genes. However, the
results presented in this paper strongly suggest that this reduction
in cell replication is due to a reduction in the new PGE2 synthesis
by the NSAID, and hence the reduction in COX-2 gene expression
and decrease in cell growth. It is therefore interesting to speculate
whether NSAIDs can potentially be used as chemopreventive
agents against the development of prostate cancer, as has been
suggested for colon cancer (Thun et al, 1991; Earnest et al, 1992).
As with other immediate-early genes, cycloheximide increased
the steady-state COX-2 mRNA accumulation both in the absence
and presence ofdmPGE2 (Figure 7). These data suggest the pres-
ence of a protein, possibly a ribonuclease, that normally reduces
the steady-state level of cellular COX-2 mRNA, the synthesis of
which is inhibited by the protein synthesis inhibitor cyclohex-
imide. Similar effects of cycloheximide (or any other translation
inhibitor) have been observed by many investigators (Kujubu et al,
1991; Stroebel and Goppelt-Struebe, 1994), in which the most
plausible explanation is that the agents inhibit the synthesis of a
COX-2 mRNA degradation factor (Ristimaki et al, 1994). In PC-3
cells, dmPGE2 only slightly potentiated the cycloheximide-
induced COX-2 mRNA accumulation. These data suggest further
that dmPGE2-induced increase in COX-2 mRNA levels required
the synthesis of a new protein, perhaps a transcription factor,
essential for the expression ofthe COX-2 gene.
In conclusion, we have shown evidence that suggests that
dmPGE2 regulates the expression of COX-2 gene in two human
prostatic carcinoma (e.g. PC-3 and LNCaP) cell lines. This regula-
tion seems to be important in the maintenance of growth and
homeostasis ofthe prostate cancer cells, as well as other cancerous
human cells from different tissue origins (e.g. MDA-MB-134 and
DiFi cells). Indeed, the data in this paper support our hypothesis
that exogenous and newly synthesized PGE2 play a physiological
role in the regulation of COX-2 expression and the growth of
PC-3 cells, while NSAID (flurbiprofen) can down-regulate growth
and COX-2 expression. As this cell line is responsive to growth
stimulation by LA (Rose and Connolly, 1991), the fact that its
metabolite, PGE2, stimulates prostate cell growth brings us one
step closer to defining a molecular link between dietary fat and
increased cancer growth.
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